Irbesartan er metaboliseres hovedsageligt af CYP2C9 og i mindre udstrækning ved glucuronidering.
No significant pharmacokinetic or pharmacodynamic interactions were observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by CYP2C9.